NEW YORK, April 23, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding PDC Energy, Inc. (NASDAQ: PDCE), SandRidge Energy, Inc. (NYSE: SD), Thermo Fisher Scientific, Inc. (NYSE: TMO), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1468-100free.
--
PDC Energy, Inc. Analyst Notes
On April 10, 2014, PDC Energy, Inc. (PDC Energy) announced plans to release its Q1 2014 financial results before the market opens on May 6, 2014, followed by a conference call with investors to discuss the performance the same day at 11:00 a.m. ET. Analysts at Zacks Investment Research expect the Company to report adjusted diluted EPS of $0.33. In the preceding quarter ended December 31, 2013, the Company had surprised the street by reporting adjusted diluted EPS of $0.44 versus net loss of $4.25 in the corresponding quarter of the prior year. The full analyst notes on PDC Energy are available to download free of charge at:
http://www.analystsreview.com/1468-PDCE-23Apr2014.pdf
--
SandRidge Energy, Inc. Analyst Notes
On April 14, 2014, SandRidge Energy, Inc. (SandRidge Energy) announced that it will release its Q1 2014 shareholder update and financial results after the close of trading on the NYSE on May 7, 2014. The Company will also host a conference call to discuss the results the following day at 8:00 am CDT. According to Zacks Investment Research, the consensus EPS estimate for the quarter is $0.02. In the previous quarter ended December 31, 2013, the Company had posted adjusted net income of $14.9 million, or $0.03 per diluted share, compared to adjusted net income of $35.3 million, or $0.06 per diluted share, in Q4 2012. The full analyst notes on SandRidge Energy are available to download free of charge at:
http://www.analystsreview.com/1468-SD-23Apr2014.pdf
--
Thermo Fisher Scientific, Inc. Analyst Notes
On April 14, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher) introduced a new peristaltic pump that enables researchers working in bioprocessing environments to achieve the precision and reliability needed to improve their processes. According to the Company, the Thermo Scientific Miniflex peristaltic pump delivers an expanded flow range of up to 370 mL per minute, allowing researchers to effectively dispense low- and high-volume fluids with repeatability and accuracy on a scale previously not offered by pumps of equivalent size. Thermo Fisher stated that the new Miniflex also offers small instrument footprint, offering easy integration into small space applications and continuous tubing which reduces the risk of contamination and leakage. The full analyst notes on Thermo Fisher are available to download free of charge at:
http://www.analystsreview.com/1468-TMO-23Apr2014.pdf
--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 11, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that it will report its Q1 2014 financial and operating results on May 8, 2014, at 8:30 a.m. ET, before the U.S. financial markets open. According to Bloomberg, the consensus adjusted diluted EPS estimate for the quarter is $2.34. In the previous quarter ended December 31, 2013, the Company delivered a positive surprise of 7.47% in its adjusted EPS of $2.24. Also in Q4 2013, the Company's revenues of $610.4 million, which represented a growth of 47.2% YoY, surpassed the market expectations. Analysts polled by Bloomberg had expected the Company's revenues at $581.8 million in Q4 2013. The full analyst notes on Regeneron are available to download free of charge at:
http://www.analystsreview.com/1468-REGN-23Apr2014.pdf
--
Questcor Pharmaceuticals, Inc. Analyst Notes
On April 17, 2014 Questcor Pharmaceuticals, Inc. (Questcor Pharmaceuticals) announced in a press release that it is partnering with the National Kidney Foundation to become a National Sponsor of Kidney Walk, which is the country's largest walk to raise money and awareness for kidney disease. As stated by the Company, through this partnership, Questcor will support more than 85 Kidney Walks across the country. Steve Cartt, Questcor's COO said, "Questcor is very pleased to partner with the National Kidney Foundation as a National Corporate Sponsor of Kidney Walk. As a company, we are committed to serving the needs of kidney patients, their families and the healthcare providers who care for them. Our support of the Kidney Walk helps the Foundation serve its mission to raise awareness of kidney disease and to provide lifesaving programs that directly impact kidney patients and their families." The full analyst notes on Questcor are available to download free of charge at:
http://www.analystsreview.com/1468-QCOR-23Apr2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
